Adamas Pharmaceuticals Inc.Find Ratings Reports
ADAMAS PHARMACEUTICALS INC's gross profit margin for the first quarter of its fiscal year 2020 has significantly increased when compared to the same period a year ago. Sales and net income have grown, and although the growth in revenues has outpaced the average competitor within the subsector, the net income growth has not. ADAMAS PHARMACEUTICALS INC is extremely liquid. Currently, the Quick Ratio is 5.09 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year.
At the same time, stockholders' equity ("net worth") has significantly decreased by 124.80% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY20||Q1 FY19|
|Net Sales ($mil)||14.48||11.67|
|Net Income ($mil)||-16.65||-29.66|
|Balance Sheet||Q1 FY20||Q1 FY19|
|Cash & Equiv. ($mil)||115.28||190.64|
|Total Assets ($mil)||144.31||223.23|
|Total Debt ($mil)||137.12||130.59|
|Profitability||Q1 FY20||Q1 FY19|
|Gross Profit Margin||-88.89||-225.31|
|Return on Assets||-63.87||-56.3|
|Return on Equity||0.0||-196.64|
|Debt||Q1 FY20||Q1 FY19|
|Share Data||Q1 FY20||Q1 FY19|
|Shares outstanding (mil)||28.16||27.52|
|Div / share||0.0||0.0|
|Book value / share||-0.56||2.32|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||461277.0||431934.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. Along with this, the price-to-book ratio is also meaningless due to a negative book value for the company, making any comparisons useless. The price-to-sales ratio is well below both the S&P 500 average and the subsector average, indicating a discount.
|ADMS NM||Peers 34.58||ADMS NM||Peers 47.01|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
ADMS's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
ADMS's P/CF is negative making the measure meaningless.
|ADMS NM||Peers 34.73||ADMS NA||Peers 0.82|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
ADMS's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|ADMS NM||Peers 10.18||ADMS 28.36||Peers 8.04|
Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
ADMS's P/B is negative making this valuation measure meaningless.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
ADMS is expected to have an earnings growth rate that significantly exceeds its peers.
|ADMS 1.33||Peers 545.31||ADMS 33.12||Peers 148.39|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
ADMS is trading at a significant discount to its subsector on this measurement.
Lower. A sales growth rate that trails the subsector implies that a company is losing market share.
ADMS significantly trails its peers on the basis of sales growth.